KIM
CORT icon

Kestra Investment Management’s Corcept Therapeutics CORT Stock Holding History

Kestra Investment Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,534
Closed -$211K – 441
2025
Q3 		$211K Sell
2,534
-506
-17% -$36.6K 0.01% 414
2025
Q2 		$223K Buy
3,040
+526
+21% +$38.1K 0.01% 410
2025
Q1 		$287K Buy
2,514
+1,982
+373% +$121K 0.01% 335
2024
Q4 		$26.8K Buy
+532
New +$27.9K ﹤0.01% 657

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kestra Investment Management's CORT Position: Q4 2025 in Review

Kestra Investment Management sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 2,534 shares — an estimated $211K sold.

Kestra Investment Management first reported a position in CORT in Q4 2024 and held it in 4 quarters. The position peaked at $287K in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • Kestra Investment Management reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Kestra Investment Management sold 2,534 Corcept Therapeutics shares in Q4 2025, an estimated $211K.
  • Kestra Investment Management first reported a position in Corcept Therapeutics in Q4 2024 and held it in 4 quarters.
  • Kestra Investment Management's Corcept Therapeutics position peaked at $287K in Q1 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Kestra Investment Management's 13F filing for Q4 2025, filed 9 Feb 2026.